Literature DB >> 22648708

FGFR1 expression and gene copy numbers in human lung cancer.

Lukas H Kohler1, Masoud Mireskandari, Thomas Knösel, Annelore Altendorf-Hofmann, Almut Kunze, Andreas Schmidt, Norbert Presselt, Yuan Chen, Iver Petersen.   

Abstract

FGFR1 is a receptor tyrosine kinase of which the ligands belong to the fibroblast growth factor family. To evaluate the significance of FGFR1 in lung cancer, we analysed tumours by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Tissue microarrays were constructed containing 380 lung cancer samples including squamous cell carcinomas (SCC), adenocarcinomas (ADC), non-small cell lung cancer not otherwise specified, metastases, neuroendocrine tumours, large cell lung cancer and small cell lung cancer. FGFR1 expression was analysed by IHC and scored semi-quantitatively by a four-tier approach (0, 1, 2, 3). Using dual-colour interphase FISH with probes specific for the locus on 8p12 and the centromere of chromosome 8 (CEN8), copy numbers of FGFR1 were determined. High expression of FGFR1 was associated with increased FGFR1 gene copy numbers in squamous cell carcinoma (p < 0.001). The FGFR1 locus was equally affected by copy number losses and gains. The higher FGFR1 gene copy numbers in SCC compared to ADC did not reach statistical significance. High copy number amplification of FGFR1 was a very rare event, the FGFR1/CEN8 signal ratio reaching a maximum value of 2.75. There were no significant associations between FGFR1 and clinicopathological parameters. Fibroblast growth factor signalling represents an interesting therapeutic target in lung cancer. However, the pathways are complex with potential oncogenic and anti-oncogenic activities. Our data may help to define criteria for selecting patients that may benefit from these new therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648708     DOI: 10.1007/s00428-012-1250-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  34 in total

1.  Personalized therapy of lung cancer.

Authors:  Roman Thomas; Jürgen Wolf
Journal:  Onkologie       Date:  2012-01-20

Review 2.  Mechanisms underlying differential responses to FGF signaling.

Authors:  Lisa Dailey; Davide Ambrosetti; Alka Mansukhani; Claudio Basilico
Journal:  Cytokine Growth Factor Rev       Date:  2005-03-05       Impact factor: 7.638

3.  Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma.

Authors:  Zaur Hamidov; Annelore Altendorf-Hofmann; Yuan Chen; Utz Settmacher; Iver Petersen; Thomas Knösel
Journal:  J Clin Pathol       Date:  2011-07-01       Impact factor: 3.411

Review 4.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

5.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.

Authors:  F Courjal; M Cuny; J Simony-Lafontaine; G Louason; P Speiser; R Zeillinger; C Rodriguez; C Theillet
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

6.  Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:  Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson
Journal:  Cancer Discov       Date:  2011-06       Impact factor: 39.397

7.  Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.

Authors:  Edoardo Missiaglia; Joanna Selfe; Mohamed Hamdi; Daniel Williamson; Gerben Schaaf; Cheng Fang; Jan Koster; Brenda Summersgill; Boo Messahel; Rogier Versteeg; Kathy Pritchard-Jones; Marcel Kool; Janet Shipley
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

8.  Influence of basic fibroblast growth factor on the proliferation of non-small cell lung cancer cell lines.

Authors:  Hartmut Kuhn; Carmen Köpff; Jana Konrad; Alexander Riedel; Christian Gessner; Hubert Wirtz
Journal:  Lung Cancer       Date:  2004-05       Impact factor: 5.705

9.  The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.

Authors:  Olivier E Pardo; John Latigo; Rosemary E Jeffery; Emma Nye; Richard Poulsom; Bradley Spencer-Dene; Nick R Lemoine; Gordon W Stamp; Eric O Aboagye; Michael J Seckl
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

10.  Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization.

Authors:  T Ried; I Petersen; H Holtgreve-Grez; M R Speicher; E Schröck; S du Manoir; T Cremer
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  28 in total

1.  Analysis of Chromosome 3, 7 and 8 Centromeric Regions in Bronchial Lavage Specimens by FISH.

Authors:  Sezen Atasoy; Salih Serdar Erturan; Nail Yılmaz; Dilhan Kuru; Ayşe Çırakoğlu; Şükriye Yılmaz; Ayhan Deviren
Journal:  Turk Thorac J       Date:  2016-10-01

2.  FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.

Authors:  An Na Seo; Yan Jin; Hee Jin Lee; Ping-Li Sun; Hyojin Kim; Sanghoon Jheon; Kwhanmien Kim; Choon-Taek Lee; Jin-Haeng Chung
Journal:  Virchows Arch       Date:  2014-08-03       Impact factor: 4.064

3.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

4.  High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event.

Authors:  Katinka Rüping; Annelore Altendorf-Hofmann; Yuan Chen; Eric Kampmann; Sebastian Gibis; Lars Lindner; Detlef Katenkamp; Iver Petersen; Thomas Knösel
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-08       Impact factor: 4.553

5.  Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma.

Authors:  Vitor Sousa; Diana Reis; Maria Silva; Ana Maria Alarcão; Ana Filipa Ladeirinha; Maria João d'Aguiar; Teresa Ferreira; Sandra Caramujo-Balseiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2016-05-19       Impact factor: 4.064

6.  Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer.

Authors:  Fang Yang; Yina Gao; Jingshu Geng; Di Qu; Qiuyue Han; Jiping Qi; Gongyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.

Authors:  Magnus Mathias Dötsch; Vera Kloten; Martin Schlensog; Timon Heide; Till Braunschweig; Jürgen Veeck; Iver Petersen; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2015-08-07       Impact factor: 4.528

Review 8.  Prognostic and predictive biomarkers in lung cancer. A review.

Authors:  Erik Thunnissen; Kimberly van der Oord; Michael den Bakker
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

9.  Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.

Authors:  H Kotani; H Ebi; H Kitai; S Nanjo; K Kita; T G Huynh; A Ooi; A C Faber; M Mino-Kenudson; S Yano
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

10.  Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.

Authors:  Till Sebastian Clauditz; Arne Böttcher; Henning Hanken; Kerstin Borgmann; Guido Sauter; Waldemar Wilczak; Tobias Grob; Adrian Münscher
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-11       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.